Stock Events

Stock Events

Ovid Therapeutics 

$2.66
99
-$0.09-3.27% Today

Statistics

Day High
2.77
Day Low
2.66
52W High
3.11
52W Low
0.26
Volume
317,185
Avg. Volume
2,901,298
Mkt Cap
189.42M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.21
-0.12
-0.03
0.06
Expected EPS
-0.123878
Actual EPS
N/A

Financials

-4,670.14%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.13MRevenue
-52.87MNet Income

Analyst Ratings

4.6Average Price Target
The highest estimate is 7.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OVID. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
PTC Therapeutics
PTCT
Mkt Cap5.7B
PTC Therapeutics competes in the rare diseases space, including treatments for neurological disorders, overlapping with Ovid's focus areas.
Biogen
BIIB
Mkt Cap25.38B
Biogen has a strong portfolio in neurology and rare diseases, making it a direct competitor to Ovid Therapeutics.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, including therapies for neurological disorders, competing with Ovid's approach.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals works on RNA interference (RNAi) therapeutics for genetic and rare diseases, including neurological conditions, competing with Ovid.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.71B
Acadia Pharmaceuticals specializes in CNS disorders, including rare neurological conditions, making it a competitor to Ovid.
Anavex Life Sciences
AVXL
Mkt Cap273.38M
Anavex Life Sciences Corp. focuses on developing novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, competing with Ovid.
Neurocrine Biosciences
NBIX
Mkt Cap12.94B
Neurocrine Biosciences targets neurological and endocrine diseases, including treatments that could compete with Ovid's products.

About

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Show more...
CEO
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Employees
23
Country
United States
ISIN
US6904691010

Listings

STU
DE
1OT.STU
MU
DE
1OT.MU
XNAS
US
OVID
F
DE
1OT.F

0 Comments

Share your thoughts

FAQ

What is Ovid Therapeutics stock price today?▼
The current price of OVID is $2.66 USD — it has decreased by -3.27% in the past 24 hours. Watch Ovid Therapeutics stock price performance more closely on the chart.
What is Ovid Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ovid Therapeutics stocks are traded under the ticker OVID.
Is Ovid Therapeutics stock price growing?▼
OVID stock has risen by +19.57% compared to the previous week, the month change is a +39.59% rise, over the last year Ovid Therapeutics has showed a +882.14% increase.
What is Ovid Therapeutics market cap?▼
Today Ovid Therapeutics has the market capitalization of 189.42M
When is the next Ovid Therapeutics earnings date?▼
Ovid Therapeutics is going to release the next earnings report on May 13, 2026.
What were Ovid Therapeutics earnings last quarter?▼
OVID earnings for the last quarter are 0.06 USD per share, whereas the estimation was -0.12 USD resulting in a +151.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ovid Therapeutics revenue for the last year?▼
Ovid Therapeutics revenue for the last year amounts to 1.13M USD.
What is Ovid Therapeutics net income for the last year?▼
OVID net income for the last year is -52.87M USD.
How many employees does Ovid Therapeutics have?▼
As of April 13, 2026, the company has 23 employees.
In which sector is Ovid Therapeutics located?▼
Ovid Therapeutics operates in the Health & Wellness sector.
When did Ovid Therapeutics complete a stock split?▼
Ovid Therapeutics has not had any recent stock splits.
Where is Ovid Therapeutics headquartered?▼
Ovid Therapeutics is headquartered in New York, United States.